Preclinical data has also suggested that canagliflozin may reduce infarct size [33] as well as the progression of atherosclerosis, adhesion molecules, and markers of inflammation (i.e., vascular cell adhesion molecule-1 and monocyte chemotaxis protein-1) [34]. The gene discussed is VCAM1; the disease is atherosclerosis.